Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.

Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol. 2009 Nov 20; 27(33):5650-9.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.